Forbion Growth Management B.V. — SEC Form 4 filings
SEC reporting owner CIK 1918318. 11 Form 4 filings on record with FilingPulse; latest filed 2025-01-02.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-10-18 to 2025-01-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 14 legs across 2 filings — 1,032,430 shares, $8,012,667 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 25 legs across 9 filings — 1,175,289 shares, $30,021,362 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 259,739 shares @ $25.22 ($6,550,202) in NewAmsterdam Pharma Co N.V., filed 2024-12-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | 10% owner | 9 | — | 25 legs · 1,175,289 sh · $30,021,362 | — |
| enGene Holdings Inc. (ENGN) | 10% owner | 2 | 14 legs · 1,032,430 sh · $8,012,667 | — | — |
Form 4 filings — Forbion Growth Management B.V.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-01-02 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 29,846 @ $25.54 | EDGAR |
| 2024-12-30 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 33,438 @ $26.01 · Sale (S): 41,472 @ $25.95 | EDGAR |
| 2024-12-26 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 44,143 @ $25.53 · Sale (S): 5,629 @ $26.13 · Sale (S): 25,132 @ $25.49 · Sale (S): 16,164 @ $25.66 | EDGAR |
| 2024-12-20 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 54,518 @ $25.72 · Sale (S): 46,210 @ $26.55 · Sale (S): 56,506 @ $25.45 | EDGAR |
| 2024-12-18 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 1,096 @ $25 · Sale (S): 66,648 @ $25.60 · Sale (S): 47,736 @ $26.45 | EDGAR |
| 2024-12-16 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 140,048 @ $25.25 · Sale (S): 25,963 @ $26.18 · Sale (S): 25,751 @ $25.01 | EDGAR |
| 2024-12-12 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 259,739 @ $25.22 · Sale (S): 48,511 @ $26.15 · Sale (S): 130,561 @ $25.26 · Sale (S): 18,583 @ $26.41 · Sale (S): 4,894 @ $27.11 | EDGAR |
| 2024-11-19 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 8,530 @ $25.02 · Sale (S): 33,273 @ $25.08 | EDGAR |
| 2024-11-15 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A. | Sale (S): 1,066 @ $25.00 · Sale (S): 9,832 @ $25.01 | EDGAR |
| 2024-11-01 | 4 | enGene Holdings Inc. (ENGN) jointly with Forbion Growth Opportunities Fund I Cooperatief U.A. | Purchase (P): 561,797 @ $8.90 | EDGAR |
| 2024-10-18 | 4 | enGene Holdings Inc. (ENGN) jointly with Forbion Growth Opportunities Fund I Cooperatief U.A. | Purchase (P): 2,750 @ $7.17 · Purchase (P): 5,050 @ $7.69 · Purchase (P): 400 @ $8.30 · Purchase (P): 9,620 @ $9.09 · Purchase (P): 38,396 @ $5.94 · Purchase (P): 3,243 @ $6.38 · +7 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1918318 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →